COVID-19 vaccine: protein-based Nuvaxovid available
15 avril 2022 – Following Swissmedic’s authorisation of the Nuvaxovid® / NVX-CoV2373 vaccine from Novavax, the Federal Office of Public Health (FOPH) and the Federal Vaccination Commission (EKIF) have published the corresponding vaccination recommendation. The vaccine will be delivered to Switzerland in the second quarter of 2022 and distributed immediately to the cantons. The protein-based Novavax vaccine is primarily going to be used for people who cannot be given an mRNA vaccine for medical reasons. However, it is also available to other people wishing to be vaccinated.
For more information, see here.